JP2002532406A5 - - Google Patents

Download PDF

Info

Publication number
JP2002532406A5
JP2002532406A5 JP2000587740A JP2000587740A JP2002532406A5 JP 2002532406 A5 JP2002532406 A5 JP 2002532406A5 JP 2000587740 A JP2000587740 A JP 2000587740A JP 2000587740 A JP2000587740 A JP 2000587740A JP 2002532406 A5 JP2002532406 A5 JP 2002532406A5
Authority
JP
Japan
Prior art keywords
dosage form
layer
gelatin capsule
barrier layer
forming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000587740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532406A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/030341 external-priority patent/WO2000035419A2/en
Publication of JP2002532406A publication Critical patent/JP2002532406A/ja
Publication of JP2002532406A5 publication Critical patent/JP2002532406A5/ja
Pending legal-status Critical Current

Links

JP2000587740A 1998-12-17 1999-12-10 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換 Pending JP2002532406A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11263498P 1998-12-17 1998-12-17
US60/112,634 1998-12-17
PCT/US1999/030341 WO2000035419A2 (en) 1998-12-17 1999-12-10 Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings

Publications (2)

Publication Number Publication Date
JP2002532406A JP2002532406A (ja) 2002-10-02
JP2002532406A5 true JP2002532406A5 (enExample) 2007-02-01

Family

ID=22345016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000587740A Pending JP2002532406A (ja) 1998-12-17 1999-12-10 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換

Country Status (20)

Country Link
US (2) US6419952B2 (enExample)
EP (1) EP1140012B1 (enExample)
JP (1) JP2002532406A (enExample)
KR (1) KR100634069B1 (enExample)
CN (1) CN1161101C (enExample)
AT (1) ATE260642T1 (enExample)
AU (1) AU765909C (enExample)
CA (1) CA2354472C (enExample)
CO (1) CO5271648A1 (enExample)
DE (1) DE69915346T2 (enExample)
DK (1) DK1140012T3 (enExample)
ES (1) ES2213404T3 (enExample)
HU (1) HUP0104721A3 (enExample)
IL (2) IL143691A0 (enExample)
MX (1) MXPA01006108A (enExample)
NO (1) NO20012959L (enExample)
NZ (1) NZ512410A (enExample)
PT (1) PT1140012E (enExample)
WO (1) WO2000035419A2 (enExample)
ZA (1) ZA200104928B (enExample)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
MXPA01006108A (es) * 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
CA2393601A1 (en) * 1999-12-09 2001-06-14 Alza Corporation Antiviral medication
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
AU2002355686B2 (en) * 2001-07-04 2007-11-29 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
HUP0402451A3 (en) * 2001-12-19 2008-04-28 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
CA2471081A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
MXPA05000224A (es) * 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
AR040301A1 (es) * 2002-06-28 2005-03-23 Alza Corp Composicion osmotica expansible y suspension para revestimiento mejoradas
CA2490412A1 (en) * 2002-06-28 2004-01-08 Alza Corporation Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
DK1539115T3 (da) * 2002-07-29 2008-01-28 Alza Corp Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon
USD475451S1 (en) 2002-09-09 2003-06-03 Access Business Group International Llc Vitamin tablet
BR0315454A (pt) * 2002-10-21 2005-08-23 Givaudan Sa Composições pesticidas
US20040091538A1 (en) * 2002-10-31 2004-05-13 Crystal Pollock-Dove Dosage form providing ascending release of liquid formulation
EP1556000A1 (en) * 2002-10-31 2005-07-27 Alza Corporation Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
US7037521B2 (en) * 2003-03-28 2006-05-02 Bausch & Lomb Incorporated Using a laser for cutting a hole in a capsule for controlled drug delivery
ES2379466T3 (es) 2003-06-26 2012-04-26 Psivida Us, Inc. Sistema de suministro de fármacos de liberación sostenida bioerosionables
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
SI1635787T1 (sl) * 2003-06-26 2012-04-30 Psivida Inc Bioeredibilni sistemi za oddajanje zdravil z zadrževanim sproščanjem
US20050003070A1 (en) * 2003-07-03 2005-01-06 Foster David V. Shelf stable vitamin C in oatmeal products
KR20070087194A (ko) * 2003-07-11 2007-08-27 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
SI2279729T1 (sl) * 2003-07-17 2016-10-28 Banner Life Sciences, LLC Pripravki z nadziranim sproščanjem
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050079220A1 (en) * 2003-07-31 2005-04-14 Betty Yu Osmotic engine & dosage form for controlled release of a liquid active agent formulation
SI1575565T1 (sl) * 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sproĹˇŽŤanjem
USD520635S1 (en) 2003-09-16 2006-05-09 Novartis Ag Combine capsule and tablets
USD530814S1 (en) 2003-09-16 2006-10-24 Novartis Ag Combined capsule and tablets
WO2005030180A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Osmotic dosage forms for controlled delivery of alprazolam
CA2542836A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
JP2007511519A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 液状投薬形態物におけるトピラメートの制御放出
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
JP2008520736A (ja) 2004-11-23 2008-06-19 アマダス ファーマシューティカルズ インコーポレイテッド 持続放出コーティングまたはマトリックスおよびnmda受容体アンタゴニストを含む組成物、そのようなnmdaアンタゴニストの被験体への投与方法
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
EP1827377B1 (en) * 2004-12-14 2008-03-19 Novartis AG In-situ forming implant for animals
CA2596029A1 (en) * 2005-01-27 2006-08-03 David E. Edgren Oral osmotic dosage form having a high flux membrane
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
JP5303276B2 (ja) * 2005-10-12 2013-10-02 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 25−ヒドロキシビタミンd不足および欠乏を治療するための方法および製品
US20070208041A1 (en) * 2005-10-13 2007-09-06 Stamler Jonathan S Compositions for the treatment and prevention of heart disease and methods of using same
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US20070196487A1 (en) * 2006-02-16 2007-08-23 Geerke Johan H Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
US20070281008A1 (en) * 2006-06-05 2007-12-06 Lin Shun Y Personal lubricant compositions and kits for providing personal lubrication
EP2679228B1 (en) 2006-06-21 2018-03-21 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
DE102006032426A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
DE102006032427A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
US20080038334A1 (en) * 2006-08-08 2008-02-14 John Zazula Method for producing and a system for cooling a hot-filled softgel capsule
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008093554A1 (ja) * 2007-01-30 2008-08-07 Olympus Medical Systems Corp. 管腔通過確認装置および管腔通過確認装置の製造方法
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
US8592401B2 (en) 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP3225243B1 (en) 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101759244B1 (ko) 2007-04-25 2017-07-18 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE028598T2 (en) 2007-06-08 2016-12-28 Boehringer Ingelheim Int Extended release nevirapine preparation
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
EP2219583B1 (en) * 2007-10-15 2012-11-21 Capsugel Belgium NV Method and apparatus for manufacturing filled linkers
WO2009050192A1 (en) * 2007-10-15 2009-04-23 Glaxo Group Limited Paneled capsule shells for release of pharmaceutical compositions
EP2537506A1 (en) * 2007-10-15 2012-12-26 Capsugel Belgium NV Linkers for multipart dosage forms for release of one or more parmaceutical compositions, and the resulting dosage forms
US20090110724A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of pain
US8609139B2 (en) * 2007-11-05 2013-12-17 Ala Wai Pharma, Inc. Formulations for enhanced bioavailability of orally administered polar agents
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP5783725B2 (ja) 2007-12-28 2015-09-24 インパックス ラボラトリーズ、 インコーポレイテッドImpax Laboratories, Inc. レボドパの放出制御製剤及びその使用
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
RU2011145278A (ru) * 2009-04-09 2013-05-20 Алкермес Фарма Айэленд Лимитед Композиции клозапина с контролируемым высвобождением
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
CN101596174B (zh) * 2009-07-13 2011-04-06 北京航洋胶囊技术有限公司 一种软胶囊及其制备方法
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
CA2776173A1 (en) 2009-09-30 2011-04-07 Nicholas Marini Cofactors and methods of use for individuals
AU2010308021A1 (en) 2009-10-16 2012-05-17 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ, インコーポレイテッド アマンタジン組成物および使用方法
KR20120098908A (ko) 2009-12-23 2012-09-05 아이언우드 파마슈티컬스, 인코포레이티드 Crth2 조절제
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US8486013B2 (en) * 2010-03-18 2013-07-16 Biotronik Ag Balloon catheter having coating
SI2552484T1 (sl) 2010-03-29 2020-07-31 Opko Ireland Global Holdings, Ltd. Postopki in sestavki za znižanje ravni paratiroidnega hormona
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
WO2011161666A2 (en) * 2010-06-21 2011-12-29 White Innovation Ltd. Enclosed liquid capsules
UY33476A (es) 2010-06-30 2012-02-29 Ironwood Pharmaceuticals Inc Estimuladores de sgc
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
RU2017129378A (ru) 2011-07-15 2019-02-04 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
CN103211797B (zh) * 2012-01-18 2017-06-06 北京天衡医院管理有限公司 盐酸维拉帕米膜控缓释微丸胶囊
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US20150080381A1 (en) 2012-04-12 2015-03-19 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
RU2014145682A (ru) 2012-04-14 2016-06-10 Интра-Селлулар Терапиз, Инк Органические соединения
US9661844B2 (en) * 2012-04-30 2017-05-30 Dow Agrosciences Llc Pesticide composition delivery vehicles
US11312878B2 (en) * 2012-07-23 2022-04-26 Lotte Fine Chemical Co., Ltd. Aqueous composition for preparing hard capsule, preparation method therefor, hard capsule, and method for recycling hard capsule scraps
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
EP2945616B1 (en) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Treating pulmonary conditions
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
IL285564B2 (en) 2013-03-15 2024-06-01 Cyclerion Therapeutics Inc sGC Stimulators
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
CN103315973B (zh) * 2013-05-24 2014-05-07 杭州和正医药有限公司 喹硫平的渗透泵型控释制剂
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP2839853A1 (de) * 2013-08-23 2015-02-25 LTS LOHMANN Therapie-Systeme AG Transdermales therapeutisches System mit Druckerzeugungsvorrichtung
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA3205777A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR102199596B1 (ko) * 2013-12-31 2021-01-07 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR102161001B1 (ko) * 2013-12-31 2020-09-29 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
CN106456997B (zh) 2014-02-27 2018-12-28 纽斯尔特科学公司 用于减少或预防肝性脂肪变性的组合物和方法
WO2015154030A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2016044446A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2016044447A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9808608B2 (en) * 2014-11-16 2017-11-07 International Business Machines Corporation Helical coil delivery device for active agent
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
CA3016353C (en) 2016-03-25 2021-04-27 Intra-Cellular Therapies, Inc. Deuterated fused heterocycle gamma-carbolines and compositions thereof useful in the treatment of nervous system disorders
CA3018019A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR102413459B1 (ko) * 2016-07-06 2022-06-24 듀렉트 코퍼레이션 약물 조성물, 장벽 층 및 약물 층을 갖는 경구 투여 형태
PE20190607A1 (es) 2016-09-02 2019-04-23 Ironwood Pharmaceuticals Inc Estimuladores de sgc
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US11180493B2 (en) 2016-11-08 2021-11-23 Cyclerion Therapeutics, Inc. SGC stimulators
MX2019005342A (es) 2016-11-08 2019-10-02 Cyclerion Therapeutics Inc Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc).
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス,インコーポレイティド Glp-1受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
KR102398194B1 (ko) 2017-03-24 2022-05-18 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 조성물 및 방법
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
BR112020001666A2 (pt) 2017-07-26 2020-07-21 Intra-Cellular Therapies, Inc. compostos orgânicos
KR102667268B1 (ko) 2017-07-26 2024-05-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MX2020009668A (es) 2018-03-16 2021-01-08 Intra Cellular Therapies Inc Métodos novedosos.
WO2019183546A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
CN111989158B (zh) * 2018-04-15 2022-08-12 奥普图弗卢迪克生物鉴定有限责任公司 压差辅助排水系统
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
AU2019287460B2 (en) 2018-06-11 2024-02-15 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
KR20210052472A (ko) 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
EP3898221A4 (en) 2018-12-17 2022-09-14 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
AU2020311894B2 (en) 2019-07-07 2025-06-26 Intra-Cellular Therapies, Inc. Novel methods
US11753419B2 (en) 2019-12-11 2023-09-12 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
US10940088B1 (en) * 2020-01-09 2021-03-09 King Saud University Method of preparing low dose pharmaceutical formulations
CN112641751B (zh) * 2020-09-25 2022-06-21 广州玖洲胶囊生物科技有限公司 一种羟丙甲基纤维素和卡拉胶的填充空心充液胶囊
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
WO2024145659A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
AU591171B2 (en) * 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
AU2867492A (en) * 1991-10-10 1993-05-03 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
JP3901727B2 (ja) * 1994-06-13 2007-04-04 アルザ コーポレイション 液状組成物中の医薬を投与するための剤型
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
IT1289160B1 (it) 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
MXPA01006108A (es) * 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.

Similar Documents

Publication Publication Date Title
JP2002532406A5 (enExample)
CN108721242B (zh) 药品剂型及其使用
FI97686C (fi) Menetelmä helmien valmistamiseksi tarkoituksena tuottaa hallitusti vapauttavia tuotteita
FI102515B (fi) Asymmetrisiä kalvoja käsittävä väline, joka pystyy kontrolloidusti vap auttamaan aktiivista ainetta sekä menetelmiä välineiden valmistamiseks i
US20090004281A1 (en) Multiparticulate osmotic delivery system
CA2655596C (en) Multiparticulate osmotic delivery system
ES2316791T3 (es) Forma de dosificacion controlada por difusion y metodo de fabricacion inclusive impresion tridimensional.
ES2739856T3 (es) Formulaciones de liberación modificada y procedimientos para el tratamiento de la enfermedad intestinal inflamatoria
JP5903522B1 (ja) 過活動膀胱の治療のための医薬製剤
US20100015224A1 (en) Programmable buoyant delivery technology
ITMI942484A1 (it) Composizioni farmaceutiche a rilascio controllato osmotico e per diffusione del farmaco e procedimento per la loro preparazione
CA2851765C (en) A gastroretentive dosage system and process of preparation thereof
KR20100077182A (ko) 부프로피온 하이드로브로마이드 및 그의 치료적 응용
Wang et al. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects
AU8135798A (en) Multiple unit effervescent dosage form
US20120288532A1 (en) Multi-layered, multiple unit pharmaceutical compositions
HUE026633T2 (en) Covered solid preparation
JP2006507305A (ja) 液体製剤の上昇型放出を提供する剤形
CN102764243A (zh) 一种阿司匹林脉冲释放微丸和其制剂及其制备方法
JP2005533084A (ja) 液体の有効成分の製剤を含んでなりかつ膨張可能な浸透圧組成物によりその放出を制御する経口の投薬形態
JP2010511627A (ja) 分割可能な浸透性剤形及びその使用方法
WO2006031584A2 (en) Quick dissolve medicament and method of manufacturing
HK40054573A (en) Dosage forms and use thereof
HK40057856A (en) Pharmaceutical dosage forms and use thereof
HK40057857A (en) Pharmaceutical dosage forms and use thereof